BNT162b2 mRNA 疫苗接种影响滤泡性淋巴瘤和慢性淋巴细胞白血病患者的肠道微生物组组成 BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia. PubMed 2025/02/10 发表Biomark ResQ1 · IF 14.6(JCR 2025) 靶点:CD20靶点:CD38技术:NK 细胞技术:mRNA慢性淋巴细胞白血病滤泡性淋巴瘤淋巴瘤
解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制 Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies. PubMed 2024/11/11 发表Int J Mol SciQ1 · IF 5.6(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:基因编辑技术:双特异性抗体
slan+单核细胞通过胞噬作用杀死被治疗性抗体包被的癌细胞 slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis. PubMed 2023/11/01 发表Cancer Immunol ResQ1 · IF 7.9(JCR 2025) 靶点:CD20靶点:CD38技术:NK 细胞淋巴瘤地区:欧洲
新型 NKG2D 靶向双特异性抗体增强 NK 细胞和 T 细胞对恶性 B 细胞的抗体介导杀伤 Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells. PubMed 2023/10/27 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:双特异性抗体淋巴瘤
儿童、青少年及年轻成人非霍奇金淋巴瘤的细胞与体液免疫治疗 Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma. PubMed 2023/02/02 发表Best Pract Res Clin HaematolQ2 · IF 3.4(JCR 2025) 人群:儿童人群:成人靶点:CD19靶点:CD20靶点:CD22技术:CAR-NK技术:NK 细胞技术:双特异性抗体
多色流式细胞术检测供者来源 allo-HSCT 受者微小残留病的异常:一项队列研究 Abnormalities by Multicolor Flow Cytometry for Detection of Minimal Residual Disease in Recipients of Allo-HSCT Originating from Donors: A Cohort Stud PubMed 2023/01/31 发表Turk J HaematolQ3 · IF 1.6(JCR 2025) 通过 MRD 分析检测到的 allo-HSCT 受者异常可能来源于其供者。 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:造血干细胞淋巴瘤
SUMO 化抑制剂 subasumstat 通过 IFN1 依赖性巨噬细胞和 NK 细胞刺激增强利妥昔单抗活性 The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. PubMed 2022/05/05 发表BloodQ1 · IF 23.9(JCR 2025) 靶点:CD20靶点:CD38技术:NK 细胞实体瘤淋巴瘤